Medtech layoffs are picking up as 2024 draws to a close. Sean Whooley, Associate Editor, and Chris Newmarker, Editor-in-Chief The medical device industry is closing out the year with a fresh round of layoffs. At this point, MassDevice has reported on more than 22,000 medtech job cuts across the industry since mid-2022. (Have a tip […]
Akili Interactive Labs
Virtual Therapeutics completes acquisition of Akili
Virtual Therapeutics announced today that it completed the tender offer to acquire all outstanding shares of Akili (Nasdaq:AKLI). The company initially commenced its tender offer at a price of $0.4340 per share on June 3. It expired at one minute after 11:59 p.m. EDT on July 1. As of the expiration date, nearly 70 million […]
Akili launches its over-the-counter digital ADHD treatment for Android devices
Akili (Nasdaq:AKLI) today announced the over-the-counter (OTC) availability of its EndeavorOTC digital ADHD treatment. Boston-based Akili last week announced a shift toward a non-prescription business model with its OTC offerings. In doing so, the company enacted a workforce reduction of approximately 40%. It included the elimination of the company’s field sales force and market access […]
Akili reduces workforce again in move toward non-prescription models for ADHD treatment
Akili (Nasdaq:AKLI) today announced plans for a strategic shift, including a transition from a prescription to a non-prescription business model. That shift includes a workforce reduction of approximately 40%. It includes the elimination of the company’s field sales force and market access team. That accounts for approximately two-thirds of the reduction. Akili plans to invest […]
Akili lays off 46 workers
Akili announced that its board of directors approved an operating plan for 2023 that includes a 30% workforce reduction. The Boston-based digital therapeutic developer’s reduction reaches across different areas and functions. In total, 30% of Akili’s workforce amounts to 46 employees. The company communicated the decision to employees on Jan. 12 and expects to complete […]
Akili wins CE mark for digital ADHD treatment
Akili Interactive announced today that it received CE Mark approval for its EndeavorRx video game for children with attention deficit hyperactivity disorder (ADHD). Boston-based Akili’s prescription treatment is delivered through a video game experience as a way to improve attention function as measured by computer-based testing in children between ages 8 and 12 with primarily inattentive […]
FDA clears video game Rx for kids with ADHD
Akili Interactive announced that it received FDA clearance for its EndeavorRx video game for children with attention deficit hyperactivity disorder (ADHD). Boston-based Akili’s prescription treatment is delivered through a video game experience to improve attention function as measured by computer-based testing in children between ages 8 and 12 with primarily inattentive or combined-type ADHD. EndeavorRx […]
How a video game could treat ADHD
Attention-deficit hyperactivity disorder makes it harder for people to pay attention and control impulsive behavior. It is one of the most common neurobehavioral disorders in children, according to the CDC. The treatment options for ADHD include behavioral therapy and medication intervention, but what if kids could use video games to treat the disorder? Akili Interactive, […]
Akili Interactive closes $55m Series C
Akili Interactive said today it closed a $55 million Series C round of financing to help support its novel digital treatments for cognitive dysfunction. The round was led by Temasek and joined by Baillie Gifford, Amgen Ventures, M Ventures, Jazz Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies, the Boston-based company said. Akili […]
Cardiology pioneer Dr. Geoffrey Hartzler dies at 65 | MassDevice.com On Call
MASSDEVICE ON CALL — Interventional cardiologist Dr. Geoffrey Hartzler, who pioneered angioplasty treatment for heart attack patients, died last weekend at the age of 65.
In 1981 Hartzler became the 1st to use percutaneous transluminal coronary angioplasty to treat a heart attack patient. He further refined the procedure, amid growing skepticism, and established angioplasty as the gold standard for treatment.
